Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. (Amgen): One of the best ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Get Honey for FREE today ▸ <a href=" Honey finds coupons with one click. Thanks to Honey for sponsoring! Keyboard build ...

SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term ...

Wu draws more small donations from city residents while Kraft attracts larger contributions and significant out-of-state ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

I spent $125 to see if I could replicate the high quality of Google Veo 3 videos I was seeing online. Here's what I learned.

Q1 2026 Earnings Call Transcript May 29, 2025 UiPath Inc. beats earnings expectations. Reported EPS is $0.11, expectations ...

Elastic's valuation remains attractive as growth accelerates, driven by rising adoption of Generative AI. Learn why ESTC ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

Stakeholders agree that the regulatory overhaul sends a strong signal to both local and international investors, positioning ...

Tolerance Bio is targeting an often-overlooked organ — the thymus — with cell therapy to help kids with DiGeorge syndrome, and potentially extend lifespan in adults.